LRCX · Lam Research Corporation — research history

The Form 4 cluster trigger was misleading — both recent filings (June 11 and June 12) represent open-market SALES by Director Eric Brandt under a pre-established Rule 10b5-1 plan adopted in February 2026, totaling ~107,500 shares sold at $337-$373. This is not insider buying; it is profit-taking during a +156% YTD run-up. No genuine open-market insider purchases were identified across the full 90-day window. The stock is trading at forward P/E of 46.4 against a sector median that does not justify this premium for an equipment name with ~34% China revenue concentration and significant geopolitical export-risk exposure. Earnings quality is solid (four consecutive beats), but the valuation is stretched, RSI has elevated from extreme levels, and a broad AI/semi sentiment unwind on June 23 (-9.3% day) underscores downside fragility. No asymmetric mispricing exists at current levels.

Score falls well below the 45-point threshold due to stretched valuation (46x FPE, 58.7x EV/EBITDA) and zero insider buying offset by $50M in sales. Explicit anti-signals (customer concentration, pump signals) trigger the skip gate. While IV is elevated enough for income structures, the lack of mispricing, structural concentration risk, and absence of a concrete asymmetric edge make this unsuitable for publication or paper-tracking.

LRCX is a high-quality semiconductor capital equipment company with exceptional fundamentals — 50% gross margins, 40%+ earnings growth guidance, strong FCF generation. However, the stock has rallied ~159% YTD and sits at a forward P/E of 46x vs sector median ~35x for semis equipment peers; EV/EBITDA of 58.7x is also premium. The Form 4 cluster that triggered this investigation consists entirely of pre-scheduled 10b5-1 SELLING by director Eric Brandt (June 11-12) and SVP Neil Fernandes (June 2), not open-market buying — a critical misread of the trigger signal. There are zero genuine insider purchases in recent filings. The stock is fully valued with limited margin of safety at current prices.

Rich valuation (41x Fwd PE, 52x EV/EBITDA) and lack of insider buying leave no margin of safety or mispricing edge; anti-signals for customer concentration and potential dilution further constrain the setup. Upside to consensus targets (~$375) falls short of the 20% return threshold required for publication.

Lam Research is a high-quality semiconductor equipment maker with exceptional fundamentals — 23.8% revenue growth, ~50% gross margins, and consistent EPS beats in every recent quarter (Q3 FY26: +7.9% surprise). However, the stock has run from $88 to $324 (+127%) over the past year and sits only ~7% below its all-time high, with a rich forward P/E of 41x and EV/EBITDA of 52x. No open-market insider purchases were found in the last 90 days — recent Form 4s reflect RSU vestings (A-code) and scheduled Rule 10b5-1 sales, not discretionary buys. The bullish OTM call blocks on June 9 appear speculative rather than informed. WFE demand optimism raised at BofA conference is a real catalyst for July 29 earnings, but the market has already priced much of it in. Valuation does not support an asymmetric long setup; income and range-bound strategies are the appropriate structures.

Fully valued mega-cap at all-time highs with zero insider buying, elevated anti-signals (customer concentration >30% and dilution), and no identifiable edge over the 32 sell-side analysts covering the name.

Lam Research is a world-class semiconductor capital equipment maker (deposition, etch, clean) riding a powerful AI-driven WFE expansion cycle. Fundamentals are exceptional — 4 consecutive EPS beats with an average surprise of ~8%, Q3 FY26 revenue $5.84B (+24% YoY), gross margin stable at ~50%, ROIC near 67%. However, the stock is at its all-time high ($305) and trades at a demanding 38.5x forward P/E and 48x EV/EBITDA — premium multiples for a highly cyclical equipment name exposed to geopolitical China risk (34-37% of revenue). The Salzburg AI packaging lab expansion is a real but multi-year product development thesis, not an immediate near-term re-rating catalyst. Zero open-market insider buys in the past 90 days and heavy automated selling through pre-arranged 10b5-1 plans suggest management views current valuations as appropriately set. No asymmetric mispricing exists; this is a fully-valued quality name.

The dossier explicitly notes the market has already priced in the AI capex thesis with the stock trading at a significant premium to sector peers (Fwd P/E ~38x, EV/EBITDA ~47x) and lacking insider conviction buys. With a composite score of 40 and no clear mispricing or asymmetric catalyst, this fails the core threshold to publish.

LRCX is a leading semiconductor wafer fabrication equipment maker (etch, deposition, clean) with direct AI/HBM exposure via memory customer capex and advanced packaging. The stock has surged ~252% YTD off the ~$80 low to hit $299 near its 52-week high of $302. Fundamentals are record-caliber — four consecutive quarterly EPS beats (most recent +7.9%), gross margins at ~50%, and FY2026 consensus EPS growth of ~37-40%. However, valuation is rich: forward P/E ~38x, EV/EBITDA ~47x with near-zero SOTP gap to speak of given the stock has already re-rated aggressively off AI enthusiasm. Insider form4 data shows predominantly selling in Q1/Q2 2026 (routine option exercises), not new open-market conviction buys. Options flow confirms strong call-side bias but this partly reflects hedging by a bull consensus crowd rather than contrarian signal. No smoking-gun catalyst beyond continued AI spending, which is already priced in at these levels.

Score 36 falls well below the 50-point skip threshold. LRCX trades at a valuation premium (Fwd P/E 36x vs sector 32x) with zero insider buying and active insider selling, leaving no margin of safety for a long thesis. The dossier explicitly recommends income strategies over asymmetric longs, and flagged anti-signal gates for customer concentration and dilution further limit the setup's viability.

Lam Research has surged ~300% over the past year on sustained AI-driven semiconductor equipment demand, sitting 4% below its all-time high. The company is fundamentally exceptional—four consecutive positive EPS surprises (3-10%), FY2026 EPS guidance raised to $5.675 (+37% YoY), ROIC of 66.8%, and gross margins expanding. However, at a forward P/E of 36x versus sector median ~30x, the stock leaves no valuation discount for error. Insider Form 4 filings show zero open-market purchases in the past 90 days—all recent activity was RSU vesting, option exercises, or pre-planned Rule 10b5-1 sales (e.g., S=18,170 shares by SVP Fernandes at $255 on May 1). Options flow shows a curious put-heavy volume ratio (3.64 P/C) but net dollar bullish ($192K call bias), with a large out-of-the-money $160 put strike possibly representing structural hedges rather than directional bearish bets. No mispricing exists; the stock is fully priced. The appropriate thesis is income-generation on pullbacks, not an asymmetric long.